US Exchange Filings

UFP Technologies Reports Third-Quarter Sales and Earnings Growth

UFP Technologies lifted third-quarter sales 11.6% and net income 25.8%, with MedTech demand driving growth and gross margin reaching 29.4%. Results extended a strong nine-month run as the company scales new programs and improves legacy operations.

UFP Technologies reported higher sales and earnings for the third quarter, with growth across its medical-technology business and an increase in gross margin. The contract manufacturer also posted double-digit sales growth for the first nine months of 2026 and cited progress in scaling new programs and improving margins in its legacy operations.

Key details

  • Third-quarter sales rose 11.6% to $172.4 million, from $154.6 million a year earlier. Organic sales growth was 11.1%.
  • Net income increased 25.8% to $20.6 million, compared with $16.4 million in the third quarter of 2025.
  • Earnings per diluted share were $2.64 on a GAAP basis and $2.88 on an adjusted basis. The adjusted figure is a non-GAAP measure.
  • Gross margin was 29.4% in the quarter. Adjusted operating income grew 14.5%; the company did not provide the dollar amount in the announcement.
  • MedTech sales grew 12.5% in the quarter, reflecting what the company described as broad-based demand across its portfolio.
  • For the first nine months of 2026, sales rose 10.3% to $500.6 million, from $453.9 million in the same period last year. Net income increased 16.2% to $59.0 million, from $50.7 million.
  • Nine-month diluted EPS was $7.56 on a GAAP basis and $8.28 on an adjusted basis.
  • MedTech sales were up 11.7% year to date. The company said sales to its five largest MedTech customers collectively also grew 11.7%.
  • UFP said it was scaling new programs in the Dominican Republic and making margin improvements in its legacy operations. It also pointed to returns from investments intended to broaden its capabilities.

Plain-English implications

The results show that UFP’s sales growth extended beyond a single quarter, while earnings grew faster than sales in both the quarter and the year-to-date period. MedTech was a significant source of growth, and the company highlighted improvement in gross margin and adjusted operating income alongside its sales gains.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.